MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 23, 2006; DOI: 10.1124/mol.105.021816


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.021816v1
69/6/1897    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liao, M.
Right arrow Articles by Correia, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liao, M.
Right arrow Articles by Correia, M. A.


Received for publication December 20, 2005.
Revised February 16, 2006.
Accepted for publication March 23, 2006.

ER-ASSOCIATED DEGRADATION (ERAD) OF CYTOCHROME P450 CYP3A4 IN SACCHAROMYCES CEREVISIAE: FURTHER CHARACTERIZATION OF CELLULAR PARTICIPANTS AND STRUCTURAL DETERMINANTS

Mingxiang Liao 1, Saadia Faouzi 1, Andrey Karyakin 2, Maria Almira Correia 1*

1 UCSF 2 Scripps Inst

* Address correspondence to: E-mail: mariac{at}itsa.ucsf.edu

Abstract

The monotopic, endoplasmic reticulum (ER)-anchored P450s undergo variable proteolytic turnover. CYP3A4, the dominant human liver drug-metabolizing enzyme, is degraded via ubiquitin (Ub)-dependent 26S proteasomal pathway after heterologous expression in S. cerevisiae. This turnover involves the Ub-conjugating enzyme Ubc7p, and the 19S proteasomal subunit Hrd2p, but is independent of Hrd1p/Hrd3p, a major Ub-ligase (E3) involved in ER protein degradation. We now show that CYP3A4 ERAD also involves the Ubc7p-ER anchor Cue1p, as CYP3A4 is significantly stabilized at the stationary growth phase in Cue1p-deficient yeast. To determine whether the other major Ub-ligase Doa10p or Rsp5p involved in ER protein degradation functions in CYP3A4 ERAD, wild type and Doa10p- or Rsp5p-deficient yeast strains were also similarly examined. No appreciable CYP3A4 stabilization was detected in either Doa10p- or Rsp5p-deficient yeast, thereby excluding these E3s and revealing that CYP3A4 ERAD involves a novel or as yet to be identified E3. Similar studies also revealed that the Cdc48p-Ufd1p-Hrd4p complex, responsible for the translocation of polyubiquitinated ER proteins was critical for CYP3A4 ERAD. We previously reported that grafting of the C-terminal (CT) CYP3A4 heptapeptide onto the CYP2B1 C-terminus switched its proteolytic susceptibility from predominantly vacuolar to proteasomal degradation. To determine the relevance of this CT-heptapeptide to CYP3A4 ERAD, CYP3A4 degradation after CT-heptapeptide-deletion (CYP3A4{Delta}CT) was similarly examined in yeast. These findings revealed that CYP3A4{Delta}CT was also degraded by Ubc7p-26S proteasomal pathway, thereby indicating that this CT-heptapeptide is not critical for CYP3A4 proteasomal degradation. Thus, unlike CYP2B1, CYP3A4 harbors additional/multiple structural degrons for its recruitment into the Ub-proteasomal pathway.


Key words: Structure-activity relationships and modeling, Cytochrome P450, Enzymology, Regulation - physiological, Regulation - post-transcriptional





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics